Increased risk of fungal infection detection in women using menstrual cups vs. tampons: a cross-sectional study

- Nicolas Tessandier^{1,2,*}, Ilkay Başak Uysal^{2,#}, Baptiste Elie^{2,#}, Christian
- Selinger², Claire Bernat², Vanina Boué², Sophie Grasset², Soraya Groc²,
- Tsukushi Kamiya^{1,3}, Massilva Rahmoun², Bastien Reyné², Noemi Bender⁴,
- Marine Bonneau⁵, Christelle Graf⁵, Vincent Tribout⁶, Vincent Foulongne⁷,
- Jacques Ravel⁸, Tim Waterboer⁴, Christophe Hirtz⁹, Ignacio G Bravo², Jacques
- Reynes¹⁰, Michel Segondy¹¹, Carmen Lia Murall^{2,12}, Nathalie Boulle¹³, Samuel
- 9 Alizon 1,2,*
- 1 Center for Interdisciplinary Research in Biology (CIRB), College de France, CNRS, INSERM,
- 11 Université PSL, Paris, France
- ² Laboratoire MIVEGEC (UMR CNRS 5290, IRD 224, UM), Montpellier, France
- $^{\rm 3}$ HRB Clinical Research Facility, National University of Ireland Galway, Ireland
- 4 Molecular Diagnostics of Oncogenic Infections, Infection, Inflammation and Cancer Program,
- 15 German Cancer Research Center (DKFZ), Im Neuenheimer Feld, Heidelberg, Germany.
- 5 Department of Obstetrics and Gynaecology, Centre Hospitalier Universitaire de Montpellier,
- 17 Montpellier, France
- 18 ⁶ Center for Free Information, Screening and Diagnosis (CeGIDD), Centre Hospitalier Universitaire de
- 19 Montpellier, Montpellier, France
- $^{\rm 7}$ Pathogenesis and Control of Chronic Infections, Montpellier University, INSERM, EFS, Montpellier,
- 21 France
- $^{\rm 8}$ Institute for Genome Sciences, Department of Microbiology and Immunology, University of Maryland
- 23 School of Medicine, Baltimore, MD, USA
- ⁹ LBPC/PPC- IRMB, CHU de Montpellier and Université de Montpellier, Montpellier, France
- ¹⁰ Infectious Diseases Departement, University Hospital Montpellier; INSERM U1175/Institut de
- 26 Recherche et de Developement, Unité Mixte International, Montpellier, France.
- 27 Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS, CHU
- 28 Montpellier, Montpellier, France.
- 29 12 Current address: Department of Biological Sciences, Université de Montréal, Montréal, Canada
- 30 13 Pathogenesis and Control of Chronic Infections, University of Montpellier, INSERM, EFS;
- 31 Departement of Pathology and Oncobiology, Laboratory of Solid Tumors, CHU Montpellier,
- 32 Montpellier, France.
- 33 # Equal contribution
- ^{*} Corresponding authors: nicolas.tessandier@college-de-france.fr, samuel.alizon@cnrs.fr, Collège de
- 35 France, 11 place Marcelin Berthelot, 75005 Paris, France, phone: +33 144271667
- Running title: Menstrual cup use increases fungal infection risk

37 Abstract

38

39

40

41

42

43

44

45

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

Objective: To determine if the use of menstrual cups rather than tampons is associated with more or less health risk.

Design: Analysing biological, demographic, and behavioural data in a cohort of women who reported using mostly tampons (n = 81) or menstrual cups (n = 22).

Setting: A cross-sectional analysis using the inclusion data of a single centre longitudinal study.

Population: 149 women from 18 to 25 years old living in the area of Montpellier (France) who reported having at least one new sexual partner over the last year.

Methods: Statistical modelling (mainly binomial regression models and factor analyses of mixed data).

Main Outcome Measures: Self-reported data from questionnaires (fungal infection, urinary tract infection, stress level) and biological data (HPV screening, vaginal microbiota profiling, circulating antibodies titration, and local cytokine concentrations).

Results: We identify an increased risk of reporting fungal infections for women using menstrual cups over tampons. We do not detect significant differences in terms of vaginal microbiota composition or local cytokines expression profile but find that women fall into two different clusters in a factor analysis of mixed data depending on the type of menstrual product they use more (cups or tampons).

Conclusions: These results point to potential health risks in the use of menstrual cups and differences in local vaginal environments. In-depth studies are needed to better understand potential associations between menstrual product use and women's health.

Funding: European Research Council (EVOLPROOF, grant 648963)

Ethics The PAPCLEAR study Clinical Trials gov identifier is NCT02946346.

Keywords: menstrual hygiene; women's health; vaginal microbiota; fungal infections; immunity

Tweetable abstract: A cross-sectional study finds a significant association between menstrual cup use and fungal infection risk.

Introduction

72

74

77

79

80

81

82

83

86

Menstruation is associated with reproductive health, but it also has implications beyond physical health, as recognised by the emergent concept of menstrual health [1]. Furthermore, the risks associated with menstrual poverty [2] are increasingly recognised and include for instance bacterial vaginosis [3] or reproductive tract infections [4].

The vaginal microbiota is a crucial component of women's health throughout their lives [5]. It could play a key role in preventing diseases such as yeast infections, urinary tract infections (UTI), and STIs, especially HIV [6]. Contrarily to the gut microbiota, the vaginal microbiota is associated with relatively few, clearly-defined, community state types (CST), most of which are dominated by one or two species of *Lactobacillus* bacteria [7]. The CST IV stands out because of its high diversity and prevalence of anaerobic bacteria with, therefore, an association with dysbioses. For these reasons, it could be associated with menstrual health.

The immune system (both innate and adaptive) elements of the vaginal environment have evolved to meet the special challenges that are associated with the female reproductive tract [8]. This equilibrium is tightly maintained by both sex hormones throughout the menstrual cycle and microbiota to respond to the challenges of bacteria, yeast, and viruses without interfering with events that surround conception[9]. Perturbations in either may impede the efficiency of the immune system to control pathogens and significantly compromise women's health.

Among the variety of products used during the menses, menstrual cups are perceived as a safe, practical, economical, and ecologically-friendly alternative to tampons and sanitary pads [10]. The majority of women using them report wanting to continue to use them both in high and low-income settings, showing a good level of acceptability [11, 10]. Nevertheless, there have been some reported cases of toxic shock syndrome, renal colic, and allergies associated with menstrual cup usage [10]. Moreover, higher levels of *Staphylococcus aureus* growth have been reported in menstrual cups compared to tampons [12]. However, the number of case studies is limited and we know little about potential health risks associated with cup usage compared to other menstrual hygiene products [10].

Our objective is to test whether the type of menstrual hygiene products can shape
the vaginal immunological and microbiological environment in a way that could affect
women's health. To this end, analysed biological, demographic, and behavioural longitudinal data from 149 women, in the context of the PAPCLEAR clinical study on human
papillomavirus (HPV) infections [13]. We focused in particular on the local impact of
the different product use and, using statistical modelling, identified profile differences
depending on the type of menstrual product used.

4 Materials and methods

105 Cohort description and data curation

The participants of this analysis were 149 young women from the PAPCLEAR longitudinal clinical study which started in 2016 and was finalised in 2020. The women were aged between 18-25 years, mainly students, from the area of Montpellier (France) and their human papillomavirus status, other genital infections, immunological responses (antibodies and cytokines), behaviours were followed up for two years [13].

We selected participants who reported using tampons or cups for menstrual products, and for whom detailed cytokine profiles (see below), microbiota metabarcoding data, and antibody data at the inclusion visit were available. This amounts to n = 103 women.

We assigned tampon or menstrual cup categories when a participant reported using either type of menstrual product over 75% of the time over the whole duration of the study. There was no difference in follow-up duration between women using mostly cups or mostly tampons (Table 1).

The demographic, behavioural, and biological analyses were performed on the first two visits of the participant (V1 and V2), which were spread 4 weeks apart.

120 Patient involvement

111

112

113

114

116

117

Women participating in the study benefited from free gynaecological consults and from a compensation fee, as detailed in the study protocol [13]. Furthermore, two information leaflets on HPV infections in young women and on the vaginal microbiota were written in collaboration with the University Hospital of Montpellier and handed out to study

participants upon inclusion. Finally, participants who have finished the follow-up and who accept to be informed by the scientific results of the study receive information by email.

128 Biological analyses

Antibodies were analysed according to methods from Waterboer et al. [14] and already partly analysed in Murall et al. [15] in the context of HPV infection.

The cytokine data were obtained using MesoScale discovery (MSD) technology from vaginal secretions collected using ophthalmic sponges as described in Murall et al. [13] and was already analysed in the context of HPV infections by Selinger et al. [16]. We used the same protocol to obtain normalised values (per total protein concentration).

The microbiota profiling was performed via metabarcoding using the V3-V4 region of the 16S gene, as discussed in the study protocol [13]. The assignment of the community state type was done using the VALENCIA software package [17].

138 Statistical analysis

We used binomial regression models for models in Table 1, Figure 1A, and in Extended data Tables S4 and S5. For each model, we computed the odds ratios associated with each predictor along with a 95% confidence interval. All analyses were performed in R (4.1.2) [18]. We used the glmulti function to conduct binomial regressions and selected the best model using the Akaike Information Criterion corrected for small sample sizes (AICc). We used a lowest AICc +5 interval for the most probable best models (Table S3 and S4) [19]. For clustering analysis, factor analysis of mixed data (FAMD) was used when combining both factor and numeric data (Figure 1F), and multiple correspondence analysis (MCA) was used when analysing binary data (Figure S2) [20].

148 Core outcome set

No core outcome set (COS) was used in the study. According to the CROWN database, the only potential relevant COS could have been "Heavy menstrual bleeding" but we found no general COS about menstrual health.

Data availability

The data that support the findings of this study are available from the corresponding author upon request, and from the Zenodo public repository (XXXXX) upon publication.

155 Funding

The PAPCLEAR clinical study was funded by the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme [grant agreement No 648963]. The funders played no role in conducting research and writing the manuscript.

The 103 women who could be included in the analysis were aged from 18 to 25 years old

160 Results

161

and primarily university students. Their main demographic characteristics are shown in 162 Table S1. We stratified the population according to the most frequent type of menstrual 163 product used, i.e. either tampons, n = 81 women, or menstrual cups, n = 22 (see the 164 Supplementary Methods). The self-reported stress level was the only variable for which 165 the two groups differed slightly (p - value = 0.08), with menstrual cup users reporting 166 more frequently a moderate level of stress than tampon users (Supplementary Table S1). 167 We used generalised linear models to detect potential differences in key covariates 168 (listed in Supplementary Table 2) between the two groups. The best model, according 169 to our selection approach (see Supplementary Methods), shows that a significantly lower 170 fraction of menstrual cup users identifies themselves as smokers compared to tampon 171 users (OR = 0.18) and that the fraction of women who report using menstrual cups 172 presenting a genital infection by human papillomaviruses (HPVs) is also lower (OR =173 0.36). Conversely, reporting using menstrual cups was more associated with reporting 174 a recent fungal genital infection (OR = 6.55). There was also a marginally significant 175 trend of increased risk of urinary tract infection (Table 1). Importantly, Smoking and Fungal infection were the only two covariates to be present and significant in the best 177 model and in the models comparable to it based on an Akaike Information Criterion (see 178 Supplementary Methods and Table 2).

To better understand the association between the type of menstrual products used 180 and the occurrence of fungal infections, we performed another set of generalised linear 181 models, this time evaluating the covariates associated with reporting a fungal infection. 182 The selection procedure yielded a (best) model according to which smoking (p = 0.02)183 and the use of menstrual cups (p = 0.002) were associated with a higher reporting of 184 recent fungal infection (Figure 1A). There was also a significant association between 185 being vaccinated against HPV and reporting a recent fungal infection (p = 0.02). Of 186 note, among women aged 18 to 25 years, reporting of fungal infections was less common 187 in older cohorts. (p = 0.03). The type of menstrual product used the most (cups or 188 tampons) was the only covariate present and significant in all of the 124 next best models 189 selected (Supplementary Table S3), further confirming its association with reporting 190 fungal infections in our cohort. 191

To study a potential association between the type of menstrual protection used and 192 the vaginal microbiota, we performed a 16S metabarcoding analysis (Figure 1B). We 193 found no significant difference in community state types (CST) composition (Figure 1C), 194 although there were some qualitative differences. For instance, none of the menstrual 195 cup users displayed a CST II or V [21]. We also did not find any significant differences 196 in microbiota diversity, assessed using Shannon diversity index, between women using 197 menstrual cups or tampons (Figure 1D). 198

To assess the potential effect of menstrual cups on the local immune response, we analysed cytokines and chemokine relative concentrations in cervical samples [16]. Among the 20 analytes measured, only IFN-β appeared to be significantly increased in women using cups (p = 0.044), although this association did not withstand correction 202 for multiple testing comparisons (p = 0.89) (Figure 1E).

199

200

201

203

204

205

206

207

208

209

210

Finally, we performed a profile analysis using a factor analysis of mixed data (FAMD) approach with CSTs distribution, Shannon diversity index, cytokines, and chemokines relative concentrations. The results show that women who use tampons and women using menstrual cups fall into different clusters (Figure 1F and Supplementary Figure S1), suggesting that the type of menstrual product used could be shaping the local immunological and microbial environment. Conversely, a similar multiple correspondence analysis (MCA) approach using blood seropositivity status for IgG and IgM of several sexually transmitted infections (STIs), including HPVs (see Supplementary Methods)
detected no clustering effect (Supplementary Figure S2), hinting that the women in
these two groups originate from similar populations in terms of the risk of exposition to
STIs.

215 Discussion

Menstrual cups are gaining in popularity as an environmentally sustainable and affordable type of menstrual protection [10]. However, there currently is a lack of epidemiological and biological data to assess their safety. Using the PAPCLEAR study [13], we compared microbiological, immunological, and epidemiological profiles of women depending on whether they report using mainly cups or tampons.

221 Main findings

232

233

234

235

237

238

239

We did not identify strong demographic or behavioural biases between our two popula-222 tions, except for reported stress levels. On the epidemiological side, we detected a strong 223 association between reporting using menstrual cups and recent fungal genital infections. 224 We also found a marginally significant positive association with urinary tract infections. 225 Finally, we identified a negative significant association with HPV infection. Note that 226 women using menstrual cups reported a greater number of partners and less smoking 227 than women using tampons, which suggests the decreased HPV prevalence is not due to 228 differences in sexual contact. To further understand the occurrence of fungal infections, 229 we performed another model which confirmed their strong association with menstrual 230 cup use, as well as smoking, number of partners, and vaccination against HPV. 231

Biological analyses revealed an absence of significant difference between vaginal microbiota compositions depending on the type of menstrual product used. For local cytokine and chemokine relative concentrations, only one potential difference was identified in IFN- β . However, the joint analysis of microbiota and immunological data showed that women segregate into two clusters based on the type of menstrual product they use most. Similar analyses using circulating antibodies found no such clustering patterns, which reinforces our conclusion that the two populations of women studied do not differ from an epidemiological standpoint (their past exposition to STIs being comparable) but,

potentially, from their local vaginal environment.

Strengths and limitations

241

Our study has several limitations, the strongest being the relatively small sample size of 242 the cohort used (n = 103), which was originally designed to study HPV infections. This 243 may hinder our ability to detect moderate or subtle changes induced by the menstrual 244 cups in the vaginal environment. Another limitation of the study lies in its cross-sectional 245 nature. Further longitudinal analyses would be helpful to establish long-term potential impacts of the use of menstrual cups on the local environment, for example, on the 247 vaginal microbiota composition. Finally, we cannot provide more details regarding the 248 fungal species or their abundance. From a statistical standpoint, a potential issue has to 249 do with pseudo-replication since we analyse two visits for each participant. To address it, 250 we analysed each of the two visits independently. In both cases, the associations between 251 menstrual cup use, smoking, and fungal infection were at least significant (Table S4 and 252 S5). Interestingly, for the second visit, the time frame for reporting a fungal infection 253 (since the last visit, i.e. one month) was smaller than for the inclusion visit (three months) 254 and the effect is stronger in the former case. 255 Finally, other factors have been shown to shape the vaginal environment [21]. Here, 256 we included for instance the use of lubricants in the analysis but more detailed studies 257

could also include contraception methods or probiotic use.

Interpretation 259

258

Earlier work on menstrual cup use and women's health is limited and summarised in 260 a recent meta-analysis [10]. Our results are consistent with earlier studies, which do 261 not show adverse effects on the vaginal microbiota. Unfortunately, this earlier meta-262 analysis studied infections in general and it would require a new meta-analysis to focus 263 on fungal infections in particular. However, the meta-analysis reported nine cases of 264 urinary tract complaints and we do find that menstrual cups users reported more urinary 265 tract infections than tampons users, although to a lesser extent than fungal infections. 266

Conclusion

Menstrual cups are one of the most popular alternatives to disposable menstrual products. As the demand for 'eco-friendly' and less expensive menstrual products arises, it is
crucial to better understand the effect of these products on women's health. Our findings
can help shape public health policies regarding the use of menstrual cups and underline
the need for additional studies to be conducted that incorporate epidemiological, clinical,

273 and biological outcomes.

The authors thank all participants of the PAPCLEAR study and clinical staff and nurses for their help.

277 Disclosure of Interests

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: TW serves on advisory boards for MSD (Merck) Sharp & Dohme.

281 Contributions

NT, CLM, NBo, and SA designed the study. NT, CLM, BE, BE, TK, IGB, and SA designed the experiments. CB, VB, SGro, MR, and NBe performed experiments. CH, JRa, and TW contributed reagents, materials, and analysis tools. CB, VB, SGra, SGro, MR, MB, CG, VT, VF, CLM, JRe, IGB, MSe, NBo, and SA contributed to study design, patient recruitment, and clinical data acquisition. NT, IBU, BE, BR, CS, TK, CLM, and SA performed data analyses. NT, IBU, IGB, CLM, and SA wrote the initial version of the manuscript. All authors approved the final version of the manuscript.

289 Ethics

The PAPCLEAR trial is promoted by the Centre Hospitalier Universitaire (CHU) de Montpellier and has been approved by the Comité de Protection des Personnes (CPP)

Sud Méditerranée I on 11 May 2016 (CPP number 16 42, reference number ID RCB 2016-A00712-49); by the Comité Consultatif sur le Traitement de l'Information en matière de Recherche dans le domaine de la Santé on 12 July 2016 (reference number 16.504); and by the Commission Nationale Informatique et Libertés on 16 December 2016 (reference number MMS/ABD/AR1612278, decision number DR-2016-488). This trial was authorised by the Agence Nationale de Sécurité du Médicament et des Produits de Santé on 20 July 2016 (reference 20160072000007). The ClinicalTrials.gov identifier is NCT02946346. All participants provided written informed consent.

300 Funding

This work was supported by the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme [grant agreement No 648963 to SA]. NT is an ANRS-MIE fellow. IBU is funded by the FHU INCH. TK is funded by the Fondation pour la Recherche Médicale. The sponsors had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

Bibliography

- Hennegan J, Winkler IT, Bobel C, Keiser D, Hampton J, Larsson G, Chandra-Mouli
 V, Plesons M, and Mahon T. Menstrual health: a definition for policy, practice, and
 research. Sex. Reprod. Health Matters 2021; 29. DOI: 10.1080/26410397.2021.
 1911618
- 2. Carneiro MM. Menstrual poverty: enough is enough. Women Health 2021; 61:721–2. DOI: 10.1080/03630242.2021.1970502
- 31. Phillips-Howard PA, Nyothach E, Kuile FO ter, Omoto J, Wang D, Zeh C, Onyango C, Mason L, Alexander KT, Odhiambo FO, Eleveld A, Mohammed A, Eijk AM van, Edwards RT, Vulule J, Faragher B, and Laserson KF. Menstrual cups and sanitary pads to reduce school attrition, and sexually transmitted and reproductive tract infections: a cluster randomised controlled feasibility study in rural Western Kenya. BMJ Open 2016; 6. DOI: 10.1136/bmjopen-2016-013229
- 4. Torondel B, Sinha S, Mohanty JR, Swain T, Sahoo P, Panda B, Nayak A, Bara M, Bilung B, Cumming O, Panigrahi P, and Das P. Association between unhygienic menstrual management practices and prevalence of lower reproductive tract infections: a hospital-based cross-sectional study in Odisha, India. BMC Infect Dis 2018; 18:473
- 5. Smith SB and Ravel J. The vaginal microbiota, host defence and reproductive physiology. J Physiol 2017; 595:451–63. DOI: 10.1113/JP271694
- McKinnon LR, Achilles SL, Bradshaw CS, Burgener A, Crucitti T, Fredricks DN,
 Jaspan HB, Kaul R, Kaushic C, Klatt N, Kwon DS, Marrazzo JM, Masson L,
 McClelland RS, Ravel J, Wijgert JHHM van de, Vodstrcil LA, and Tachedjian G.
 The Evolving Facets of Bacterial Vaginosis: Implications for HIV Transmission.
 AIDS Res Hum Retroviruses 2019; 35:219–28. DOI: 10.1089/aid.2018.0304
- 7. Ma B, France MT, Crabtree J, Holm JB, Humphrys MS, Brotman RM, and Ravel J. A comprehensive non-redundant gene catalog reveals extensive within-community intraspecies diversity in the human vagina. Nat Commun 2020; 11:940
- 8. Zhou JZ, Way SS, and Chen K. Immunology of the Uterine and Vaginal Mucosae.
 Trends Immunol 2018 Apr; 39:302–14
- 9. Wira CR, Rodriguez-Garcia M, and Patel MV. The role of sex hormones in immune
 protection of the female reproductive tract. Nat Rev Immunol 2015 Apr; 15:217–30

- H, Laserson K, and Phillips-Howard PA. Menstrual cup use, leakage, acceptability, safety, and availability: a systematic review and meta-analysis. Lancet Public Health 2019; 4:e376–e393. DOI: 10.1016/S2468-2667(19)30111-2
- North BB and Oldham MJ. Preclinical, clinical, and over-the-counter postmarketing experience with a new vaginal cup: menstrual collection. J Womens Health 2011; 20:303–11. DOI: 10.1089/jwh.2009.1929
- Nonfoux L, Chiaruzzi M, Badiou C, Baude J, Tristan A, Thioulouse J, Muller D, Prigent-Combaret C, and Lina G. Impact of Currently Marketed Tampons and Menstrual Cups on *Staphylococcus aureus* Growth and Toxic Shock Syndrome Toxin 1 Production *In Vitro*. Appl. Environ. Microbiol. 2018; 84. DOI: 10.1128/AEM. 00351-18
- 13. Murall CL, Rahmoun M, Selinger C, Baldellou M, Bernat C, Bonneau M, Boué 352 V, Buisson M, Christophe G, D'Auria G, Taroni FD, Foulongne V, Froissart R, 353 Graf C, Grasset S, Groc S, Hirtz C, Jaussent A, Lajoie J, Lorcy F, Picot E, Picot 354 MC, Ravel J, Reynes J, Rousset T, Seddiki A, Teirlinck M, Tribout V, Tuaillon É, 355 Waterboer T, Jacobs N, Bravo IG, Segondy M, Boulle N, and Alizon S. Natural 356 history, dynamics, and ecology of human papillomaviruses in genital infections of 357 young women: Protocol of the PAPCLEAR cohort study. BMJ Open 2019; 9:25129. 358 DOI: 10.1136/bmjopen-2018-025129 359
- Waterboer T, Sehr P, Michael KM, Franceschi S, Nieland JD, Joos TO, Templin MF, and Pawlita M. Multiplex human papillomavirus serology based on in situpurified glutathione s-transferase fusion proteins. Clin Chem 2005; 51:1845–53
- Murall CL, Reyné B, Selinger C, Bernat C, Boué V, Grasset S, Groc S, Rahmoun
 M, Bender N, Bonneau M, Foulongne V, Graf C, Picot E, Picot MC, Tribout V, Waterboer T, Bravo IG, Reynes J, Segondy M, Boulle N, and Alizon S. HPV cervical infections and serological status in vaccinated and unvaccinated women.
 Vaccine 2020; 38:8167-74. DOI: 10.1016/j.vaccine.2020.10.078
- Selinger C, Rahmoun M, Murall CL, Bernat C, Boué V, Bonneau M, Graf C,
 Grasset S, Groc S, Reynes J, Hirtz C, Jacobs N, and Alizon S. Cytokine response
 following perturbation of the cervicovaginal milieu during HPV genital infection.
 Immunol. Res. 2021; 69:255–63. DOI: 10.1007/S12026-021-09196-2
- France MT, Ma B, Gajer P, Brown S, Humphrys MS, Holm JB, Waetjen LE, Brotman RM, and Ravel J. VALENCIA: a nearest centroid classification method

- for vaginal microbial communities based on composition. Microbiome 2020; 8:166.

 DOI: 10.1186/s40168-020-00934-6
- R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. Vienna, Austria, 2021. Available from: https://www.R-project.org/
- 379 19. Burnham K and Anderson D. Model Selection and Inference: A Practical Information-380 Theoretic Approach. 2. 2002:75
- 20. Lê S, Josse J, and Husson F. FactoMineR: An R Package for Multivariate Analysis.

 Journal of Statistical Software 2008; 25:1–18. DOI: 10.18637/jss.v025.i01
- 21. Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL, Karlebach S, Gorle R, Russell J, Tacket CO, Brotman RM, Davis CC, Ault K, Peralta L, and Forney LJ. Vaginal microbiome of reproductive-age women. Proc Nat Acad Sci USA 2011; 108:4680–7. DOI: 10.1073/pnas.1002611107

Table 1: Association between menstrual cups usage in comparison with tampons. Results show the odds ratio (OR) of the factors selected in the best generalised linear model against menstrual cup as the response variable and using an Akaike Information Criterion corrected for small sample size (AICc). SE stands for standard error and CI for confidence interval.

Model [1]: Menstrual cup	OR	OR SE	CI 2.5%	CI 95%	p.value	
Urinary tract infection	3.45	2.37	0.86	13.37	0.07	•
Smoking	0.18	0.10	0.06	0.49	0.001	**
HPV positive (focal)	0.36	0.18	0.13	0.92	0.04	*
Number of partners over the last 12 months	1.04	0.02	1.00	1.08	0.04	*
Fungal infection	6.55	4.22	1.86	24.10	0.004	**

^{**}p < 0.01; *p < 0.05; • p < 0.1

Model [1]: Menstrual cup	Presence in best models (#)	Presence in best models (%)	$\begin{array}{c} \text{p.value} \\ < 0.1 (\%) \end{array}$	p.value < 0.05(%)
Smoking	93	100	100	100
Fungal infection	93	100	100	100
HPV positive (focal)	72	77.42	73.12	45.16
Number of partners over the last 12 months	71	76.34	46.24	21.51
Urinary tract infection	53	56.99	37.63	0
Age	40	43.01	19.35	0
Menses	19	20.43	0	0
HPV positive (multiple)	20	21.51	0	0
Lubricant	19	20.43	0	0
Intercourse with an occasional partner (last week)	14	15.05	0	0
Intercourse with a regular partner (last week)	13	13.98	0	0
Vaccinated against HPV	16	17.2	0	0
Stress level (1)	2	2.15	0	0
Stress level (2)	2	2.15	0	0
Stress level (3 (Max))	2	2.15	0	0

Table 2: Proportion of covariables presence among the 93 best models (Model 1) selected by AICc (AICc + 5)




Figure 1: Epidemiological, microbiological, and immunological differences between women using mainly menstrual cups or tampons. A) Odds ratio of covariates associated with the risk of fungal infection detection, B) Abundance and diversity of the main bacterial species found in participants, C) Community State Types (CST) distribution, D) Shannon diversity index, E) Cytokines local concentrations (log), and F) Outcome of a multi-parametric clustering analysis using factor analysis of mixed data (FAMD). In A, red indicates significance (p < 0.05) and blue indicates non-significance. In D, E, and F, colours show the type of menstrual product used (tampons in blue and cups in yellow). In F, the CSTs are shown in red.